Bibliografisk note

Funding Information:
This study was supported by Aage Bangs Foundation, Roberts Wehnerts and Kirsten Wehnerts Foundation, Liv Bryhns Foundation, Grosserer Fogts Foundation, The LEO Foundation and The Novo Nordisk Foundation Center for Basic Metabolic Research.

Funding Information:
TT has been an investigator for Novartis, Abbvie, Dr. Wolff, Galderma and Almirall. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb and Janssen Pharmaceuticals. CZ has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novatis, Sanofi, Leo pharma, UCB, CSL and Almirall. LS has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Celegene, Leo pharma, BMS, UCB and BI outside the submitted work. LS reports non‐financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen, BMS and Sanofi. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre at the University of Copenhagen that is partially funded by an unrestricted donation from the Novo Nordisk Foundation. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript.